Slingshot members are tracking this event:

Immunomedics releases Phase 2 study results on IMMU-132, as data show SACITUZUMAB GOVITECAN produces strong response in triple-negative breast cancer patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
IMMU Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 15, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Sacituzumab Govitecan, Triple Negative Breast Cancer, Phase 2, Immu-132